Because of the crucial role of PPAR-γ in regulating glucose and lipid homeostasis, synthetic PPAR-γ agonists such as thiazolidinediones, including rosiglitazone and pioglitazone, have been used to treat hyperglycemia, insulin resistance, and dyslipidemia [7]. The gene discussed is PPARG; the disease is Insulin resistance.